Pacific Edge’s Cxbladder Triage Gains Recognition in AUA Guidelines

Pacific Edge Limited ( (PFGTF) ) has provided an announcement.

Pacific Edge Limited has announced that the American Urological Association (AUA) has updated its clinical guidelines to include Cxbladder Triage as the standard of care for managing patients with microhematuria. This inclusion, based on Grade A evidence from a randomized controlled trial, positions Cxbladder Triage as a leading diagnostic tool for intermediate-risk patients, potentially increasing demand for the test. The guideline change is expected to enhance Pacific Edge’s market presence and influence ongoing policy discussions with Medicare regarding coverage. This development underscores the company’s commitment to advancing diagnostic standards and creating value for stakeholders.

More about Pacific Edge Limited

Pacific Edge Limited is a cancer diagnostics company that specializes in developing and commercializing diagnostic tests for the early detection and management of cancer. Their primary product, Cxbladder, is a non-invasive urine-based test used to detect bladder cancer, and the company focuses on improving patient care through innovative diagnostic solutions.

YTD Price Performance: -51.43%

Average Trading Volume: 10,272

Technical Sentiment Consensus Rating: Strong Buy

Current Market Cap: $27.74M

For an in-depth examination of PFGTF stock, go to TipRanks’ Stock Analysis page.